Skip to content
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Subscribe
Insights
All Insights
In My Opinion
In Your Practice
Patient Populations
News
All News
Recent Updates
FDA Approvals
Clinical Trials
Conference Correspondent
Explore by Topic
All Topics
Cancer Types
Therapeutic Approaches
Diagnostics & Biomarkers
Multimedia
All Media
Videos
Podcasts
Subscribe
Subscribe
Real Clinics. Real Patients. Real Oncology.
Home
/
Topics
/
Therapeutic Approaches
/
Immunotherapy
Home /
Immunotherapy
Immunotherapy
Immunotherapy
In Your Practice
Community Practices Cite Cost, Need for Prospective Data as Barriers to Biomarker Testing in Endometrial Cancer
July 17, 2026
Clinical Trials
New Trial Data Reshaping Patient Selection for Bladder Cancer Maintenance Immunotherapy
July 14, 2026
Clinical Trials
Enfortumab Vedotin Plus Pembrolizumab Combo Shows Promise for Cisplatin-Ineligible Bladder Cancer
June 26, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
June 26, 2026
Recent Updates
Ivonescimab Plus Chemotherapy Extends OS in Advanced Squamous NSCLC
June 1, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
May 29, 2026
In Your Practice
Navigation Refresh: Navigating Patients Receiving Immuno-Oncology Therapy
Mandi L. Pratt-Chapman
, PhD, MA, HON-OPN-CG
April 10, 2026
In Your Practice
Community Practices Cite Cost, Need for Prospective Data as Barriers to Biomarker Testing in Endometrial Cancer
July 17, 2026
Clinical Trials
New Trial Data Reshaping Patient Selection for Bladder Cancer Maintenance Immunotherapy
July 14, 2026
Clinical Trials
Enfortumab Vedotin Plus Pembrolizumab Combo Shows Promise for Cisplatin-Ineligible Bladder Cancer
June 26, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
June 26, 2026
Recent Updates
Ivonescimab Plus Chemotherapy Extends OS in Advanced Squamous NSCLC
June 1, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
May 29, 2026
In Your Practice
Navigation Refresh: Navigating Patients Receiving Immuno-Oncology Therapy
Mandi L. Pratt-Chapman
, PhD, MA, HON-OPN-CG
April 10, 2026
News & Insights
In Your Practice
Community Practices Cite Cost, Need for Prospective Data as Barriers to Biomarker Testing in Endometrial Cancer
July 17, 2026
Clinical Trials
New Trial Data Reshaping Patient Selection for Bladder Cancer Maintenance Immunotherapy
July 14, 2026
Clinical Trials
Enfortumab Vedotin Plus Pembrolizumab Combo Shows Promise for Cisplatin-Ineligible Bladder Cancer
June 26, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
June 26, 2026
Recent Updates
Ivonescimab Plus Chemotherapy Extends OS in Advanced Squamous NSCLC
June 1, 2026
Clinical Trials
Pembrolizumab-Chemo Combo Enhances Advanced Endometrial Cancer Care
May 29, 2026
In Your Practice
Navigation Refresh: Navigating Patients Receiving Immuno-Oncology Therapy
Mandi L. Pratt-Chapman
, PhD, MA, HON-OPN-CG
April 10, 2026
Podcasts
No results were found
What are you looking for?
Search
Search
POPULAR SEARCHES
Bladder Cancer
Blood-Based Tests
Breast Cancer
Cancer Types
